SHILPAMED.NSSHILPAMED.NSNSE
Loading
Net Income Growth Recovery in ProgressRecovering
Percentile Rank44
3Y CAGR-73.7%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
-73.7%/yr
vs -31.7%/yr prior
Acceleration
-42.1pp
Decelerating
Percentile
P44
Within normal range
vs 3Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 1.17% |
| Q3 2025 | -6.01% |
| Q2 2025 | 223.15% |
| Q1 2025 | -54.35% |
| Q4 2024 | 77.19% |
| Q3 2024 | 27.56% |
| Q2 2024 | -42.61% |
| Q1 2024 | 434.93% |
| Q4 2023 | 184.21% |
| Q3 2023 | 36.69% |
| Q2 2023 | 114.66% |
| Q1 2023 | -21.49% |
| Q4 2022 | 64.53% |
| Q3 2022 | -2299.27% |
| Q2 2022 | -97.13% |
| Q1 2022 | 208.93% |
| Q4 2021 | -52.08% |
| Q3 2021 | 1156.86% |
| Q2 2021 | -81.14% |
| Q1 2021 | 9.83% |
| Q4 2020 | -83.10% |
| Q3 2020 | -47.42% |
| Q2 2020 | 149.64% |
| Q1 2020 | -37.21% |
| Q4 2019 | 8.44% |
| Q3 2019 | 222.52% |
| Q2 2019 | -34.08% |
| Q1 2019 | 91.48% |
| Q4 2018 | -70.49% |
| Q3 2018 | 25.64% |
| Q2 2018 | 10.77% |
| Q1 2018 | 75.51% |
| Q4 2017 | -49.33% |
| Q3 2017 | 38.68% |
| Q2 2017 | -31.78% |
| Q1 2017 | 116.82% |
| Q4 2016 | -49.27% |
| Q3 2016 | 122.97% |
| Q2 2016 | -59.99% |
| Q1 2016 | 18.43% |